In a report released today, Peter Lawson from Barclays maintained a Hold rating on Relay Therapeutics (RLAY – Research Report), with a price target of $15.00. The company’s shares closed yesterday at $7.08.
According to TipRanks, Lawson is a 4-star analyst with an average return of 7.2% and a 44.47% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Biomea Fusion, and Exelixis.
Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $22.00.
Based on Relay Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $83.5 million. In comparison, last year the company earned a revenue of $253 thousand and had a GAAP net loss of $67.5 million
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLAY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Relay Therapeutics (RLAY) Company Description:
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
